2016 - 2022年美国医疗保险D部分受益人使用克霉唑倍他米松二丙酸酯（一种外用皮质类固醇 - 抗真菌复方产品）的处方情况
Prescribing of clotrimazole-betamethasone dipropionate, a topical combination corticosteroid-antifungal product, for Medicare part D beneficiaries, United States, 2016-2022.
作者信息
Currie Dustin W, Caplan Avrom S, Benedict Kaitlin, Hatfield Kelly M, Smith Dallas J, Lipner Shari R, Gold Jeremy A W
机构信息
Centers for Disease Control and Prevention, Atlanta, GA, USA.
The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
出版信息
Antimicrob Steward Healthc Epidemiol. 2024 Oct 17;4(1):e174. doi: 10.1017/ash.2024.435. eCollection 2024.
During 2016-2022, Medicare part D beneficiaries filled 8,674,460 clotrimazole-betamethasone dipropionate prescriptions. Annual rates were stable (30.9 prescriptions/1,000 beneficiary-years in 2022, enough for one in every 33 beneficiaries). Diagnostic testing was infrequent, particularly among internal medicine, family medicine, and general practitioners, suggesting potential opportunities to improve diagnostic and prescribing practices.
在2016年至2022年期间，医疗保险D部分的受益人开具了8,674,460份克霉唑-倍他米松二丙酸酯处方。年开具率稳定（2022年为每1000受益人次30.9份处方，每33名受益人中就有一人足够使用）。诊断测试并不常见，尤其是在内科、家庭医学和全科医生中，这表明在改善诊断和处方实践方面存在潜在机会。
Zotero 插件